Global Incretin-Based Drugs Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Incretin-Based Drugs market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Incretin-Based Drugs market."
Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4).
Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition. 
This has resulted in a strong need for better therapeutics such as incretin based drugs. 
Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells.

The global Incretin-Based Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Incretin-Based Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Incretin-Based Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    GlaxoSmithKline
    Johnson & Johnson
    Merck & Co
    AstraZeneca
    Novartis
    Eli Lilly and Company
    Boehringer Ingelheim
    Takeda Pharmaceutical Company
    Sanofi

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Glucagon-like peptide-1 receptor (GLP-1) agonists
    Dipeptidyl Peptidase-4 (DPP-4) inhibitors

Segment by Application
    Oral Drugs
    Injectable Drugs